{"id":"W4411026697","doi":"10.1200/jco.2025.43.17_suppl.lba1005","title":"A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Western University; Hôpital du Saint-Sacrement; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Royal Victoria Regional Health Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Fulvestrant; Medicine; Estrogen receptor; HER2 negative; Metastatic breast cancer; Palbociclib; Placebo; Internal medicine; Double blind; Cyclin-dependent kinase; Breast cancer; Oncology; Estrogen; Cancer; Pathology; Cell cycle","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002627038,0.002844346,0.004713712,0.0006693706,0.0006737753,0.001546043,0.001550474,0.003161442,0.01374988],"category_scores_gemma":[0.002685416,0.00116574,0.001880101,0.0006012296,0.002123355,0.001803182,0.0006378185,0.004693088,0.002729021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074181,"about_ca_system_score_gemma":0.002139942,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009910398,"about_ca_topic_score_gemma":0.00304383,"domain_scores_codex":[0.9991117,0.0004016163,0.00005846459,0.0001829326,0.00007294086,0.0001723893],"domain_scores_gemma":[0.9986664,0.0003014707,0.0003308628,0.0001133008,0.0001131654,0.0004748086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9845735,0.008833911,0.000111911,0.000360402,0.0002894468,0.0000151397,0.00002513087,0.0001331594,0.001266746,0.00008058923,0.0006107912,0.003699113],"study_design_scores_gemma":[0.9637737,0.03525383,0.0002588896,0.000014863,0.00009343297,0.000008325422,0.000006901661,0.0001164763,0.0001027127,0.00008571243,0.0002792295,0.000005922985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.937665,0.005609886,0.001859022,0.00202402,0.002766221,0.03751741,0.004813269,0.0005254612,0.007219788],"genre_scores_gemma":[0.9368265,0.003922422,0.003035125,0.003323985,0.001297982,0.03656191,0.002772134,0.00006832002,0.01219158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01374988,"threshold_uncertainty_score":0.04599798,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05781636090479739,"score_gpt":0.4786090012652857,"score_spread":0.4207926403604882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}